直接作用型抗ウイルス薬市場 - 世界の産業規模、動向、機会、予測、2018年～2028年、タイプ別、適応症別、ルート別、流通経路別、地域別、競合

世界の直接作用型抗ウイルス薬市場は、予測期間中に目覚ましい成長を遂げると予測されています。

世界の直接作用型抗ウイルス薬市場は、特定のウイルス、特にC型肝炎ウイルス（HCV）とB型肝炎ウイルス（HBV）を直接標的とする抗ウイルス薬の開発と商業化に焦点を当てた製薬産業の一分野です。これらの医薬品は、従来の治療法に比べてより効果的で忍容性の高い治療法を提供することで、ウイルス感染症の治療に革命を起こすのに役立っています。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別（NS3/4Aプロテアーゼ、NS5Aタンパク質、NS5B RNA依存性RNAポリメラーゼ）
  • 適応症別（C型肝炎ウイルス、HIV感染症/エイズ、インフルエンザ、予防薬）
  • ルート別（静脈内、経口、皮下、局所）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • 薬剤タイプ別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 地域別

第6章 北米の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 国別
• 北米国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの直接作用型抗ウイルス薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 適応症別
  • ルート別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Natco Pharma Ltd
• Vertex Pharmaceuticals Inc
• Dr Reddy's Laboratories Ltd
• Johnson & Johnson
• Merck & Co Inc
• Gilead Sciences Inc
• AbbVie Inc
• Bristol-Myers Squibb Co

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Direct-acting Antiviral Drug Market is anticipated to project impressive growth in the forecast period. The global direct-acting antiviral drug market is a segment of the pharmaceutical industry focused on the development and commercialization of antiviral medications that directly target specific viruses, particularly hepatitis C virus (HCV) and hepatitis B virus (HBV). These drugs have been instrumental in revolutionizing the treatment of viral infections by providing more effective and tolerable therapies compared to traditional treatments.

Key Market Drivers

High Efficacy and Improved Cure Rates

In recent years, the global pharmaceutical landscape has witnessed a transformative shift in the treatment of viral infections, thanks to the advent of direct-acting antiviral drugs (DAAs). These innovative medications have demonstrated exceptional efficacy and improved cure rates, redefining the approach to managing viral diseases.

The hallmark of direct-acting antiviral drugs is their remarkable efficacy in combating specific viral infections, such as hepatitis C and hepatitis B. Unlike traditional treatments, which often had limited success and significant side effects, DAAs offer a game-changing solution. With cure rates that consistently exceed 95%, these drugs have raised hopes for millions of patients afflicted by these viruses.

The high efficacy of direct-acting antiviral drugs translates into significantly improved patient outcomes. Patients who undergo DAA therapy experience a higher likelihood of viral clearance, leading to not only symptomatic relief but also the prevention of disease progression. In the context of hepatitis C, for example, successful treatment can halt the advancement of liver fibrosis, cirrhosis, and the development of hepatocellular carcinoma.

Another critical aspect of the efficacy of DAAs is their potential to reduce the transmission of viral infections. With viral loads significantly reduced or eliminated in treated individuals, the likelihood of spreading the infection to others diminishes substantially. This is particularly crucial in the case of hepatitis B and C, where transmission can occur through various routes, including blood-to-blood contact and sexual intercourse.

In addition to high efficacy, direct-acting antiviral drugs offer shorter treatment durations compared to their predecessors. Traditional therapies for viral infections, such as interferon-based regimens, often required extended courses of treatment that could span several months or even a year. In contrast, DAA therapies typically range from 8 to 12 weeks. This shorter duration not only improves patient compliance but also reduces the burden on healthcare systems.

Direct-acting antiviral drugs are known for their improved tolerability. Patients undergoing DAA treatment report fewer and less severe side effects compared to older therapies. This not only enhances the overall treatment experience but also increases the likelihood that patients will complete the prescribed course of medication, further contributing to improved cure rates.

The high efficacy and improved cure rates of DAAs instill confidence in both patients and healthcare providers. Patients are more inclined to seek treatment when they know there is a high likelihood of success, while healthcare professionals are encouraged by the prospect of offering treatments that can genuinely transform the lives of their patients.

Shorter Treatment Durations

The global pharmaceutical industry has witnessed a remarkable transformation in recent years, thanks to the advent of direct-acting antiviral drugs (DAAs). One of the most significant factors driving the growth of the global direct-acting antiviral drug market is the shorter treatment durations offered by these medications.

Direct-acting antiviral drugs have ushered in a new era in the management of viral infections, particularly hepatitis C and hepatitis B. Unlike earlier treatments that often-required prolonged regimens extending up to a year or more, DAAs are known for their significantly shorter treatment durations. These durations typically range from 8 to 12 weeks, representing a substantial reduction in the time required for antiviral therapy.

One of the most significant advantages of shorter treatment durations is improved patient compliance. Traditional therapies, characterized by long and often grueling courses of treatment, posed significant challenges for patients. The extended duration of treatment could lead to treatment fatigue, missed doses, and treatment discontinuation. With DAAs, patients are more likely to adhere to the prescribed regimen due to the relatively short timeframe, resulting in better treatment outcomes.

Shorter treatment durations not only benefit patients but also alleviate the burden on healthcare systems. Prolonged treatments require more frequent medical visits, monitoring, and healthcare resources. In contrast, DAAs, with their abbreviated treatment schedules, reduce the demand on healthcare infrastructure, making it easier for healthcare providers to manage a larger volume of patients.

The cost-effectiveness of DAAs is closely tied to their shorter treatment durations. While these drugs may be relatively expensive, the overall cost of treatment is reduced when considering factors such as fewer medical visits, laboratory tests, and the potential avoidance of complications associated with prolonged illness. This cost-efficiency is an essential driver for both healthcare systems and patients.

Shorter treatment durations not only save time but also contribute to an improved quality of life for patients. Traditional antiviral treatments often came with debilitating side effects that could persist for months. In contrast, DAAs are known for their improved tolerability, reducing the impact of treatment on patients' daily lives and overall well-being.

The shorter treatment durations offered by DAAs often result in faster viral suppression. This rapid reduction in viral load can provide patients with symptomatic relief sooner, improving their overall health and reducing the risk of disease progression. Additionally, faster viral suppression can contribute to the prevention of further transmission of the virus.

Fewer Side Effect

In the ever-evolving landscape of pharmaceuticals, direct-acting antiviral drugs (DAAs) have emerged as a game-changer in the treatment of viral infections, particularly hepatitis C and hepatitis B. Among the various factors driving the growth of the global direct-acting antiviral drug market, the significantly fewer side effects associated with these medications stand out as a critical catalyst.

The hallmark of direct-acting antiviral drugs is their superior tolerability profile compared to traditional antiviral treatments. Previous therapies often came with a host of debilitating side effects, including flu-like symptoms, fatigue, depression, and anemia. In contrast, DAAs are known for their mild and manageable side effect profiles, significantly improving the overall treatment experience for patients.

Fewer side effects translate to improved patient adherence to prescribed treatment regimens. Patients are more likely to adhere to a therapy that does not disrupt their daily lives with severe and unpleasant side effects. This enhanced adherence contributes to higher cure rates and better long-term outcomes for individuals living with viral infections.

The reduced side effect burden associated with DAAs results in an improved quality of life for patients undergoing treatment. Traditional antiviral therapies could lead to a significant deterioration in the patient's well-being, affecting their ability to work, socialize, and engage in daily activities. DAAs offer a reprieve from these adverse effects, allowing patients to maintain a better overall quality of life during treatment.

Fewer side effects also have a positive economic impact on healthcare systems. The management of side effects often necessitates additional medical visits, medications, and laboratory tests, which can contribute to higher healthcare costs. With DAAs, the reduced need for supportive care and monitoring results in cost savings for both patients and healthcare providers.

The improved tolerability of DAAs has led to greater patient acceptance of antiviral treatment. Patients who may have been hesitant to pursue therapy in the past due to fear of side effects are now more willing to seek treatment. This expanded patient pool contributes to the growth of the DAA market.

The milder side effects associated with DAAs enable patients to recover more quickly from the adverse effects of viral infections. This faster recovery not only alleviates the patient's suffering but also contributes to shorter overall treatment durations, reducing the burden on healthcare systems.

Rising Prevalence of Viral Infections

The global healthcare landscape is facing a significant challenge in the form of rising prevalence rates of viral infections. Among the array of responses to this global health concern, direct-acting antiviral drugs (DAAs) have emerged as a beacon of hope.

The world is grappling with an increase in viral infections, notably hepatitis C and hepatitis B. These infections can lead to severe liver disease, cirrhosis, and even hepatocellular carcinoma if left untreated. The alarming rise in viral hepatitis cases has spurred a sense of urgency among healthcare providers, governments, and pharmaceutical companies to develop effective treatment strategies.

Direct-acting antiviral drugs have revolutionized the treatment landscape for viral infections. Their high efficacy rates have set a new standard in the field. DAAs have consistently demonstrated cure rates exceeding 95% for hepatitis C, offering an effective solution for a significant portion of those affected by the virus.

Improved awareness and diagnostics have played a crucial role in identifying more cases of viral infections. As healthcare systems enhance their screening and diagnostic capabilities, an increasing number of individuals are being diagnosed with hepatitis C and hepatitis B. This trend has created a growing pool of patients seeking treatment.

Many countries and global health organizations have launched ambitious programs aimed at eliminating viral hepatitis as a public health threat. The World Health Organization (WHO) has set targets for reducing new hepatitis infections and increasing access to treatment. Such initiatives drive the demand for effective antiviral medications like DAAs.

Governments and non-governmental organizations worldwide are taking steps to expand access to direct-acting antiviral drugs. Access programs, subsidies, and negotiations with pharmaceutical companies are making these life-saving medications more widely available to those in need, particularly in low- and middle-income countries.

Key Market Challenges

High Treatment Costs

One of the most significant challenges is the high cost of direct-acting antiviral drugs. While these medications are highly effective, their price tags can be prohibitive for many patients, especially in low- and middle-income countries. Striking a balance between recouping research and development costs and ensuring affordable access is a persistent challenge.

Access Disparities

Access to direct-acting antiviral drugs is not uniform across the globe. Disparities exist between high-income and low-income countries, as well as within countries themselves. This access gap is often exacerbated by factors such as healthcare infrastructure, government policies, and pharmaceutical pricing strategies.

Drug Resistance

Over time, the development of drug-resistant strains of viruses is a concern. While direct-acting antiviral drugs have shown remarkable efficacy, the risk of resistance remains, particularly if patients do not adhere to prescribed treatment regimens. Pharmaceutical companies must continually invest in research to develop new drugs that combat resistant strains.

Key Market Trends

Expanded Indications

One significant trend in the DAA market is the exploration of expanded indications. While DAAs have been predominantly used to treat hepatitis C and B, researchers are investigating their efficacy against other viral infections. This could lead to the development of new DAA therapies targeting a broader range of viruses.

Combination Therapies

Combination therapies, which involve the use of multiple direct-acting antiviral drugs simultaneously, are gaining traction. These regimens aim to improve treatment efficacy, reduce the risk of drug resistance, and offer more options for patients with complex medical histories or co-infections.

Generic Competition

As patents expire for some DAA medications, the market is seeing increased competition from generic versions. This trend has the potential to enhance accessibility and affordability for patients globally, particularly in lower-income regions.

Segmental Insights

Type Insights

Based on the category of Type, NS3/4A Protease is poised to dominate the Global Direct-acting Antiviral Drug Market and maintain its supremacy during the forecast years due to several compelling factors. Firstly, its efficacy in combating hepatitis C, a major global health concern, has been well-documented and widely acknowledged. This track record of success has established NS3/4A Protease as a trusted and reliable treatment option among healthcare professionals and patients alike. Moreover, ongoing research and development efforts are continuously enhancing its capabilities, ensuring its relevance in the evolving landscape of antiviral drugs. Additionally, the market's increasing demand for highly effective and targeted treatments, coupled with the growing awareness of the importance of early intervention in viral infections, will further bolster NS3/4A Protease's market presence. In conclusion, the combination of its proven effectiveness, ongoing innovation, and market demand positions NS3/4A Protease as the frontrunner in the Global Direct-acting Antiviral Drug Market for the foreseeable future.

Distribution Channel Insights

Based on Distribution Channel, Hospital Pharmacies are poised to dominate the Global Direct-acting Antiviral Drug Market and maintain their leadership in the forecast years for several compelling reasons. Firstly, hospital pharmacies offer a centralized and controlled environment for the storage and distribution of critical antiviral drugs, ensuring their availability to patients in need. This centralized approach simplifies inventory management and minimizes the risk of drug shortages, a key concern in the healthcare sector. Furthermore, hospitals often serve as the primary point of care for patients with complex medical conditions, including viral infections, making them the natural hub for dispensing these specialized medications. Additionally, the increasing prevalence of viral diseases and the need for prompt and accurate diagnosis and treatment further solidify the role of hospital pharmacies in the market. Their close collaboration with healthcare professionals and access to cutting-edge research and clinical trials also position hospital pharmacies as the go-to source for the latest and most effective antiviral treatments. In conclusion, the pivotal role that hospital pharmacies play in patient care and their ability to provide comprehensive solutions make them the dominant force in the Global Direct-acting Antiviral Drug Market, with a strong likelihood of maintaining this position in the forecasted years.

Regional Insights

North America is set to dominate the Global Direct-acting Antiviral Drug Market for several compelling reasons. Firstly, the region benefits from a robust healthcare infrastructure and a well-established pharmaceutical industry that actively drives research, development, and distribution of cutting-edge antiviral medications. Secondly, North America faces a significant burden of viral diseases, including hepatitis C and HIV, which has led to substantial investments in antiviral drug research and development. Moreover, the region's regulatory agencies maintain stringent standards, ensuring the safety and efficacy of drugs, which instills confidence among healthcare professionals and patients alike. Additionally, the region's high healthcare expenditure and insurance coverage contribute to greater accessibility to advanced antiviral treatments, fostering market growth. Furthermore, North America has a strong presence of key pharmaceutical companies, fostering innovation and competition, ultimately bolstering its dominant position in the Global Direct-acting Antiviral Drug Market. In summary, the combination of a robust healthcare ecosystem, disease prevalence, regulatory rigor, and industry innovation makes North America a formidable force in this market, poised to maintain its dominance in the years to come.

Key Market Players

• Natco Pharma Ltd

• Vertex Pharmaceuticals Inc

• Dr Reddy's Laboratories Ltd

• Johnson & Johnson

• Merck & Co Inc

• Gilead Sciences Inc

• AbbVie Inc

• Bristol-Myers Squibb Co

Report Scope:

In this report, the Global Direct-acting Antiviral Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Direct-acting Antiviral Drug Market, By Type:

• NS3/4A Protease
• NS5A Protein
• NS5B RNA-Dependent RNA polymerase

Direct-acting Antiviral Drug Market, By Indication:

• Hepatitis C Virus
• HIV Infection/ AIDS
• Influenza
• Prophylaxis

Direct-acting Antiviral Drug Market, By Route:

• Intravenous
• Oral
• Subcutaneous
• Topical

Direct-acting Antiviral Drug Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Direct-acting Antiviral Drug Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Direct-acting Antiviral Drug Market.

Available Customizations:

• Global Direct-acting Antiviral Drug market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Direct-acting Antiviral Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 5.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 5.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Indication
  • 5.3.3. By Route
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. North America Direct-acting Antiviral Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 6.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 6.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Direct-acting Antiviral Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Route
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Direct-acting Antiviral Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Route
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Direct-acting Antiviral Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Route
      • 6.3.3.2.4. By Distribution Channel

7. Europe Direct-acting Antiviral Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 7.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 7.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 7.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Direct-acting Antiviral Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Route
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. United Kingdom Direct-acting Antiviral Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Route
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. France Direct-acting Antiviral Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Route
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Direct-acting Antiviral Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Route
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Direct-acting Antiviral Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Route
      • 7.3.5.2.4. By Distribution Channel

8. Asia-Pacific Direct-acting Antiviral Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 8.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 8.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 8.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Direct-acting Antiviral Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Route
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Japan Direct-acting Antiviral Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Route
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. India Direct-acting Antiviral Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Route
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. Australia Direct-acting Antiviral Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Route
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. South Korea Direct-acting Antiviral Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Route
      • 8.3.5.2.4. By Distribution Channel

9. South America Direct-acting Antiviral Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 9.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 9.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 9.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Direct-acting Antiviral Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Route
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Direct-acting Antiviral Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Route
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Direct-acting Antiviral Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Route
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Direct-acting Antiviral Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase)
  • 10.2.2. By Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza, Prophylaxis)
  • 10.2.3. By Route (Intravenous, Oral, Subcutaneous, Topical)
  • 10.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Direct-acting Antiviral Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Route
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Direct-acting Antiviral Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Route
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Direct-acting Antiviral Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Route
      • 10.3.3.2.4. By Distribution Channel
  • 10.3.4. Kuwait Direct-acting Antiviral Drug Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Type
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Route
      • 10.3.4.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Natco Pharma Ltd
  • 14.6.2. Vertex Pharmaceuticals Inc
  • 14.6.3. Dr Reddy's Laboratories Ltd
  • 14.6.4. Johnson & Johnson
  • 14.6.5. Merck & Co Inc
  • 14.6.6. Gilead Sciences Inc
  • 14.6.7. AbbVie Inc
  • 14.6.8. Bristol-Myers Squibb Co

15. Strategic Recommendations

16. About Us & Disclaimer